Peptide vaccines in breast cancer: The immunological basis for clinical response
This review discusses peptide-based vaccines in breast cancer, immune responses and clinical outcomes, which include studies on animal models and phase I, phase I/II, phase II and phase III clinical trials. Peptide-based vaccines are powerful neoadjuvant immunotherapies that can directly target prot...
Gespeichert in:
| Veröffentlicht in: | Biotechnology advances 2015-12, Vol.33 (8), p.1868-1877 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1877 |
|---|---|
| container_issue | 8 |
| container_start_page | 1868 |
| container_title | Biotechnology advances |
| container_volume | 33 |
| creator | de Paula Peres, Lívia da Luz, Felipe Andrés Cordero dos Anjos Pultz, Brunna Brígido, Paula Cristina de Araújo, Rogério Agenor Goulart, Luiz Ricardo Silva, Marcelo José Barbosa |
| description | This review discusses peptide-based vaccines in breast cancer, immune responses and clinical outcomes, which include studies on animal models and phase I, phase I/II, phase II and phase III clinical trials. Peptide-based vaccines are powerful neoadjuvant immunotherapies that can directly target proteins expressed in tumor cells, mainly tumor-associated antigens (TAAs). The most common breast cancer TAA epitopes are derived from MUC1, HER2/neu and CEA proteins. Peptides derived from TAAs could be successfully used to elicit CD8 and CD4 T cell-specific responses. Thus, choosing peptides that adapt to natural variations of human leukocyte antigen (HLA) genes is critical. The most attractive advantage is that the target response is more specific and less toxic than for other therapies and vaccines. Prominent studies on NeuVax — E75 (epitope for HER2/neu and GM-CSF) in breast cancer and DPX-0907 (HLA-A2-TAAs) expressed in breast cancer, ovarian and prostate cancer have shown the efficacy of peptide-based vaccines as neoadjuvant immunotherapy against cancer. Future peptide vaccine strategies, although a challenge to be applied in a broad range of breast cancers, point to the development of degenerate multi-epitope immunogens against multiple targets. |
| doi_str_mv | 10.1016/j.biotechadv.2015.10.013 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1786187528</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0734975015300483</els_id><sourcerecordid>1786187528</sourcerecordid><originalsourceid>FETCH-LOGICAL-c440t-8a9094f483636ea54b9199448cd40ebe557d553b89eb18be17d8630b7a15ad0e3</originalsourceid><addsrcrecordid>eNqNkU1PGzEQhq2qqAToX0A-ctnFju213RtFtCAhkQOcLX9MiqPddWpvIvHvcQi0R3IaaeaZGel9EMKUtJTQ7nLVupgm8M82bNs5oaK2W0LZFzSjSrKGKq2_ohmRjDdaCnKMTkpZkQoSwb6h43kn5kwqMkOLBaynGABvrfdxhILjiF0GWybs7egh_8CPz4DjMGzG1Kc_0dseO1tiwcuUse_j-NbKUNZpLHCGjpa2L_D9vZ6ip183j9e3zf3D77vrq_vGc06mRllNNF9yxTrWgRXcaao158oHTsCBEDIIwZzS4KhyQGVQHSNOWipsIMBO0cX-7jqnvxsokxli8dD3doS0KYZK1dUsxFwdgtY4iGLyAJTrjnLRsYqqPepzKiXD0qxzHGx-MZSYnSWzMv8tmZ2l3aRaqqvn7182boDwb_FDSwV-7gGoCW4jZFN8hGojxAx-MiHFz7-8AuPwpzE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1749614563</pqid></control><display><type>article</type><title>Peptide vaccines in breast cancer: The immunological basis for clinical response</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>de Paula Peres, Lívia ; da Luz, Felipe Andrés Cordero ; dos Anjos Pultz, Brunna ; Brígido, Paula Cristina ; de Araújo, Rogério Agenor ; Goulart, Luiz Ricardo ; Silva, Marcelo José Barbosa</creator><creatorcontrib>de Paula Peres, Lívia ; da Luz, Felipe Andrés Cordero ; dos Anjos Pultz, Brunna ; Brígido, Paula Cristina ; de Araújo, Rogério Agenor ; Goulart, Luiz Ricardo ; Silva, Marcelo José Barbosa</creatorcontrib><description>This review discusses peptide-based vaccines in breast cancer, immune responses and clinical outcomes, which include studies on animal models and phase I, phase I/II, phase II and phase III clinical trials. Peptide-based vaccines are powerful neoadjuvant immunotherapies that can directly target proteins expressed in tumor cells, mainly tumor-associated antigens (TAAs). The most common breast cancer TAA epitopes are derived from MUC1, HER2/neu and CEA proteins. Peptides derived from TAAs could be successfully used to elicit CD8 and CD4 T cell-specific responses. Thus, choosing peptides that adapt to natural variations of human leukocyte antigen (HLA) genes is critical. The most attractive advantage is that the target response is more specific and less toxic than for other therapies and vaccines. Prominent studies on NeuVax — E75 (epitope for HER2/neu and GM-CSF) in breast cancer and DPX-0907 (HLA-A2-TAAs) expressed in breast cancer, ovarian and prostate cancer have shown the efficacy of peptide-based vaccines as neoadjuvant immunotherapy against cancer. Future peptide vaccine strategies, although a challenge to be applied in a broad range of breast cancers, point to the development of degenerate multi-epitope immunogens against multiple targets.</description><identifier>ISSN: 0734-9750</identifier><identifier>EISSN: 1873-1899</identifier><identifier>DOI: 10.1016/j.biotechadv.2015.10.013</identifier><identifier>PMID: 26523780</identifier><language>eng</language><publisher>England: Elsevier Inc</publisher><subject>Antigens ; Antigens, Neoplasm - immunology ; Breast ; Breast cancer ; Breast cancer immunotherapy ; Breast cancer therapy ; Breast Neoplasms - immunology ; Breast Neoplasms - prevention & control ; Cancer ; CD4-Positive T-Lymphocytes - immunology ; Clinical Trials as Topic ; Effectiveness ; Epitopes - immunology ; Female ; HLA-A2 Antigen - immunology ; Humans ; Peptide-based vaccines ; Peptides ; Peptides - immunology ; Peptides - therapeutic use ; Proteins ; Receptor, ErbB-2 - antagonists & inhibitors ; Receptor, ErbB-2 - immunology ; Therapy ; Tumor-associated antigens ; Vaccines ; Vaccines, Subunit - immunology ; Vaccines, Subunit - therapeutic use</subject><ispartof>Biotechnology advances, 2015-12, Vol.33 (8), p.1868-1877</ispartof><rights>2015 Elsevier Inc.</rights><rights>Copyright © 2015 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c440t-8a9094f483636ea54b9199448cd40ebe557d553b89eb18be17d8630b7a15ad0e3</citedby><cites>FETCH-LOGICAL-c440t-8a9094f483636ea54b9199448cd40ebe557d553b89eb18be17d8630b7a15ad0e3</cites><orcidid>0000-0002-5807-4286</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0734975015300483$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26523780$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>de Paula Peres, Lívia</creatorcontrib><creatorcontrib>da Luz, Felipe Andrés Cordero</creatorcontrib><creatorcontrib>dos Anjos Pultz, Brunna</creatorcontrib><creatorcontrib>Brígido, Paula Cristina</creatorcontrib><creatorcontrib>de Araújo, Rogério Agenor</creatorcontrib><creatorcontrib>Goulart, Luiz Ricardo</creatorcontrib><creatorcontrib>Silva, Marcelo José Barbosa</creatorcontrib><title>Peptide vaccines in breast cancer: The immunological basis for clinical response</title><title>Biotechnology advances</title><addtitle>Biotechnol Adv</addtitle><description>This review discusses peptide-based vaccines in breast cancer, immune responses and clinical outcomes, which include studies on animal models and phase I, phase I/II, phase II and phase III clinical trials. Peptide-based vaccines are powerful neoadjuvant immunotherapies that can directly target proteins expressed in tumor cells, mainly tumor-associated antigens (TAAs). The most common breast cancer TAA epitopes are derived from MUC1, HER2/neu and CEA proteins. Peptides derived from TAAs could be successfully used to elicit CD8 and CD4 T cell-specific responses. Thus, choosing peptides that adapt to natural variations of human leukocyte antigen (HLA) genes is critical. The most attractive advantage is that the target response is more specific and less toxic than for other therapies and vaccines. Prominent studies on NeuVax — E75 (epitope for HER2/neu and GM-CSF) in breast cancer and DPX-0907 (HLA-A2-TAAs) expressed in breast cancer, ovarian and prostate cancer have shown the efficacy of peptide-based vaccines as neoadjuvant immunotherapy against cancer. Future peptide vaccine strategies, although a challenge to be applied in a broad range of breast cancers, point to the development of degenerate multi-epitope immunogens against multiple targets.</description><subject>Antigens</subject><subject>Antigens, Neoplasm - immunology</subject><subject>Breast</subject><subject>Breast cancer</subject><subject>Breast cancer immunotherapy</subject><subject>Breast cancer therapy</subject><subject>Breast Neoplasms - immunology</subject><subject>Breast Neoplasms - prevention & control</subject><subject>Cancer</subject><subject>CD4-Positive T-Lymphocytes - immunology</subject><subject>Clinical Trials as Topic</subject><subject>Effectiveness</subject><subject>Epitopes - immunology</subject><subject>Female</subject><subject>HLA-A2 Antigen - immunology</subject><subject>Humans</subject><subject>Peptide-based vaccines</subject><subject>Peptides</subject><subject>Peptides - immunology</subject><subject>Peptides - therapeutic use</subject><subject>Proteins</subject><subject>Receptor, ErbB-2 - antagonists & inhibitors</subject><subject>Receptor, ErbB-2 - immunology</subject><subject>Therapy</subject><subject>Tumor-associated antigens</subject><subject>Vaccines</subject><subject>Vaccines, Subunit - immunology</subject><subject>Vaccines, Subunit - therapeutic use</subject><issn>0734-9750</issn><issn>1873-1899</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkU1PGzEQhq2qqAToX0A-ctnFju213RtFtCAhkQOcLX9MiqPddWpvIvHvcQi0R3IaaeaZGel9EMKUtJTQ7nLVupgm8M82bNs5oaK2W0LZFzSjSrKGKq2_ohmRjDdaCnKMTkpZkQoSwb6h43kn5kwqMkOLBaynGABvrfdxhILjiF0GWybs7egh_8CPz4DjMGzG1Kc_0dseO1tiwcuUse_j-NbKUNZpLHCGjpa2L_D9vZ6ip183j9e3zf3D77vrq_vGc06mRllNNF9yxTrWgRXcaao158oHTsCBEDIIwZzS4KhyQGVQHSNOWipsIMBO0cX-7jqnvxsokxli8dD3doS0KYZK1dUsxFwdgtY4iGLyAJTrjnLRsYqqPepzKiXD0qxzHGx-MZSYnSWzMv8tmZ2l3aRaqqvn7182boDwb_FDSwV-7gGoCW4jZFN8hGojxAx-MiHFz7-8AuPwpzE</recordid><startdate>20151201</startdate><enddate>20151201</enddate><creator>de Paula Peres, Lívia</creator><creator>da Luz, Felipe Andrés Cordero</creator><creator>dos Anjos Pultz, Brunna</creator><creator>Brígido, Paula Cristina</creator><creator>de Araújo, Rogério Agenor</creator><creator>Goulart, Luiz Ricardo</creator><creator>Silva, Marcelo José Barbosa</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7QO</scope><scope>7T5</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>P64</scope><scope>7U5</scope><scope>L7M</scope><orcidid>https://orcid.org/0000-0002-5807-4286</orcidid></search><sort><creationdate>20151201</creationdate><title>Peptide vaccines in breast cancer: The immunological basis for clinical response</title><author>de Paula Peres, Lívia ; da Luz, Felipe Andrés Cordero ; dos Anjos Pultz, Brunna ; Brígido, Paula Cristina ; de Araújo, Rogério Agenor ; Goulart, Luiz Ricardo ; Silva, Marcelo José Barbosa</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c440t-8a9094f483636ea54b9199448cd40ebe557d553b89eb18be17d8630b7a15ad0e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Antigens</topic><topic>Antigens, Neoplasm - immunology</topic><topic>Breast</topic><topic>Breast cancer</topic><topic>Breast cancer immunotherapy</topic><topic>Breast cancer therapy</topic><topic>Breast Neoplasms - immunology</topic><topic>Breast Neoplasms - prevention & control</topic><topic>Cancer</topic><topic>CD4-Positive T-Lymphocytes - immunology</topic><topic>Clinical Trials as Topic</topic><topic>Effectiveness</topic><topic>Epitopes - immunology</topic><topic>Female</topic><topic>HLA-A2 Antigen - immunology</topic><topic>Humans</topic><topic>Peptide-based vaccines</topic><topic>Peptides</topic><topic>Peptides - immunology</topic><topic>Peptides - therapeutic use</topic><topic>Proteins</topic><topic>Receptor, ErbB-2 - antagonists & inhibitors</topic><topic>Receptor, ErbB-2 - immunology</topic><topic>Therapy</topic><topic>Tumor-associated antigens</topic><topic>Vaccines</topic><topic>Vaccines, Subunit - immunology</topic><topic>Vaccines, Subunit - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>de Paula Peres, Lívia</creatorcontrib><creatorcontrib>da Luz, Felipe Andrés Cordero</creatorcontrib><creatorcontrib>dos Anjos Pultz, Brunna</creatorcontrib><creatorcontrib>Brígido, Paula Cristina</creatorcontrib><creatorcontrib>de Araújo, Rogério Agenor</creatorcontrib><creatorcontrib>Goulart, Luiz Ricardo</creatorcontrib><creatorcontrib>Silva, Marcelo José Barbosa</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Biotechnology Research Abstracts</collection><collection>Immunology Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Solid State and Superconductivity Abstracts</collection><collection>Advanced Technologies Database with Aerospace</collection><jtitle>Biotechnology advances</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>de Paula Peres, Lívia</au><au>da Luz, Felipe Andrés Cordero</au><au>dos Anjos Pultz, Brunna</au><au>Brígido, Paula Cristina</au><au>de Araújo, Rogério Agenor</au><au>Goulart, Luiz Ricardo</au><au>Silva, Marcelo José Barbosa</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Peptide vaccines in breast cancer: The immunological basis for clinical response</atitle><jtitle>Biotechnology advances</jtitle><addtitle>Biotechnol Adv</addtitle><date>2015-12-01</date><risdate>2015</risdate><volume>33</volume><issue>8</issue><spage>1868</spage><epage>1877</epage><pages>1868-1877</pages><issn>0734-9750</issn><eissn>1873-1899</eissn><abstract>This review discusses peptide-based vaccines in breast cancer, immune responses and clinical outcomes, which include studies on animal models and phase I, phase I/II, phase II and phase III clinical trials. Peptide-based vaccines are powerful neoadjuvant immunotherapies that can directly target proteins expressed in tumor cells, mainly tumor-associated antigens (TAAs). The most common breast cancer TAA epitopes are derived from MUC1, HER2/neu and CEA proteins. Peptides derived from TAAs could be successfully used to elicit CD8 and CD4 T cell-specific responses. Thus, choosing peptides that adapt to natural variations of human leukocyte antigen (HLA) genes is critical. The most attractive advantage is that the target response is more specific and less toxic than for other therapies and vaccines. Prominent studies on NeuVax — E75 (epitope for HER2/neu and GM-CSF) in breast cancer and DPX-0907 (HLA-A2-TAAs) expressed in breast cancer, ovarian and prostate cancer have shown the efficacy of peptide-based vaccines as neoadjuvant immunotherapy against cancer. Future peptide vaccine strategies, although a challenge to be applied in a broad range of breast cancers, point to the development of degenerate multi-epitope immunogens against multiple targets.</abstract><cop>England</cop><pub>Elsevier Inc</pub><pmid>26523780</pmid><doi>10.1016/j.biotechadv.2015.10.013</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0002-5807-4286</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0734-9750 |
| ispartof | Biotechnology advances, 2015-12, Vol.33 (8), p.1868-1877 |
| issn | 0734-9750 1873-1899 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1786187528 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Antigens Antigens, Neoplasm - immunology Breast Breast cancer Breast cancer immunotherapy Breast cancer therapy Breast Neoplasms - immunology Breast Neoplasms - prevention & control Cancer CD4-Positive T-Lymphocytes - immunology Clinical Trials as Topic Effectiveness Epitopes - immunology Female HLA-A2 Antigen - immunology Humans Peptide-based vaccines Peptides Peptides - immunology Peptides - therapeutic use Proteins Receptor, ErbB-2 - antagonists & inhibitors Receptor, ErbB-2 - immunology Therapy Tumor-associated antigens Vaccines Vaccines, Subunit - immunology Vaccines, Subunit - therapeutic use |
| title | Peptide vaccines in breast cancer: The immunological basis for clinical response |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T21%3A01%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Peptide%20vaccines%20in%20breast%20cancer:%20The%20immunological%20basis%20for%20clinical%20response&rft.jtitle=Biotechnology%20advances&rft.au=de%20Paula%20Peres,%20L%C3%ADvia&rft.date=2015-12-01&rft.volume=33&rft.issue=8&rft.spage=1868&rft.epage=1877&rft.pages=1868-1877&rft.issn=0734-9750&rft.eissn=1873-1899&rft_id=info:doi/10.1016/j.biotechadv.2015.10.013&rft_dat=%3Cproquest_cross%3E1786187528%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1749614563&rft_id=info:pmid/26523780&rft_els_id=S0734975015300483&rfr_iscdi=true |